Last updated: February 24, 2026
What is the Drug Associated with NDC 23155-0832?
NDC 23155-0832 is associated with Pazopanib (brand: Votrient), an oral tyrosine kinase inhibitor used primarily for renal cell carcinoma and soft tissue sarcoma. It was approved by the FDA in 2009 [1].
Market Overview
The global pazopanib market is driven by its approval for multiple indications, primarily in oncology. As of 2023, the key factors influencing this market include:
- Market Size & Revenue: The 2022 global oncology drugs market was valued at approximately $165 billion, with TKIs representing a significant portion.
- Market Penetration: Pazopanib holds a notable share within tyrosine kinase inhibitors used for renal cell carcinoma, competing with drugs such as sunitinib and cabozantinib.
- Patient Population: Estimated at 68,000 new renal cell carcinoma cases annually worldwide [2], with a smaller subset eligible for pazopanib.
Competitive Landscape
| Drug |
Indication |
Years on Market |
Market Share (2022) |
Price (USD, per 200 mg tablet) |
Key Competitors |
| Pazopanib |
Renal cell carcinoma, soft tissue sarcoma |
14 years |
22% |
$70–90 |
Sunitinib, Axitinib, Cabozantinib |
| Sunitinib |
Multiple cancers |
17 years |
30% |
$68–85 |
Pazopanib, Regorafenib |
| Cabozantinib |
Renal and medullary thyroid cancers |
8 years |
15% |
$125–150 |
Pazopanib, Sunitinib |
Source: IQVIA, 2023; SSR Health, 2022
Price Trend Analysis
Historical Price Trends
From 2019 to 2023, the price per 200 mg tablet has remained relatively stable, with minimal fluctuations. Price increases are primarily related to inflation adjustments and market factors, not new patent protections or regulatory changes.
Future Price Projections (2024–2028)
| Year |
Estimated Price Range per 200 mg Tablet |
Key Factors |
| 2024 |
$73–$95 |
Patent expiry for some formulations, inflation, increased manufacturing costs |
| 2025 |
$76–$98 |
Entry of biosimilars in some regions, generic competition in select markets |
| 2026 |
$78–$100 |
Patent expirations in additional regions, price negotiations |
| 2027 |
$80–$102 |
Increased biosimilar market entry, competitive pricing pressures |
| 2028 |
$82–$105 |
Market stabilization, volume increases, pricing strategies |
Impact of Patent Expiry and Biosimilars
The patent for pazopanib is expected to expire in the US by 2028 [3]. Biosimilar and generic competition could reduce the cost per tablet by 20–30% in North American and European markets post-expiry.
Regulatory and Policy Influence
- Price controls in certain countries (e.g., NHS in the UK) could cap prices, limiting revenue growth.
- US Medicare and Medicaid negotiations could apply pressure for price reductions.
- Orphan drug status may extend exclusivity in some regions, delaying generic entry.
Key Market Dynamics
- Expanding Indications: Ongoing clinical trials for other cancers can extend patent protections and sustain pricing.
- Market Access Strategies: Pharma companies often use patient assistance programs to improve access, influencing sales volume.
- Pricing Strategies: Tiered pricing in emerging markets may lower average prices but expand volume.
Conclusions
Pazopanib (NDC 23155-0832) maintains a competitive position in the kidney and soft tissue sarcoma market. Price points are stable; significant reductions are anticipated post-patent expiration, with biosimilar entry expected to accelerate in 2028. Strategic focus on expanding indications and negotiating payor agreements will impact future revenue.
Key Takeaways
- The current price per tablet hovers around $70–$90, reflecting stability over recent years.
- Market share is approximately 22%, dominated by sunitinib.
- The upcoming patent expiry in 2028 will likely trigger generic and biosimilar competition, reducing prices.
- Market growth hinges on new indications and access to emerging markets.
- Regulatory policies will influence pricing trajectories, especially in restrictive health systems.
FAQs
1. How does the patent expiry of pazopanib influence its market price?
Patent expiry generally leads to generic and biosimilar competition, which reduces product prices due to increased supply and competition.
2. What are the main competitors to pazopanib?
Sunitinib, cabozantinib, and axitinib are the main competitors within the same therapeutic class, competing for market share in renal cell carcinoma treatment.
3. Will biosimilar versions significantly decrease costs?
Biosimilars could reduce prices by 20–30% in regions where they receive approval and market access, primarily post-2028.
4. How does market penetration vary globally?
Market penetration is higher in developed regions like North America and Europe, with emerging markets showing slower adoption due to reimbursement and access issues.
5. What clinical developments could alter future pricing?
New indications, improved formulations, or breakthroughs in treatment efficacy could justify higher prices or extend market exclusivity.
References
[1] U.S. Food and Drug Administration. (2009). FDA Approves Votrient for Kidney Cancer.
[2] American Cancer Society. (2022). Key Statistics for Renal Cell Carcinoma.
[3] FDA Orange Book. (2023). Patent and Exclusivity Data for Pazopanib.
[4] IQVIA. (2023). Global Oncology Market Data.
[5] SSR Health. (2022). Oncology Drug Market Shares.
